Literature DB >> 10940229

Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library.

N Reixach1, E Crooks, J M Ostresh, R A Houghten, S E Blondelle.   

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder characterized by the deposit of amyloid fibrils in the brain that result from the self-aggregative polymerization of the beta-amyloid peptide (Abeta). Evidence of a direct correlation between the ability of Abeta to form stable aggregates in aqueous solution and its neurotoxicity has been reported. The cytotoxic effects of Abeta have been attributed to the aggregation properties of a domain corresponding to the peptide fragment Abeta25-35. In an effort to generate novel inhibitors of Abeta neurotoxicity and/or aggregation, a mixture-based synthetic combinatorial library composed of 23 375 imidazopyridoindoles was generated and screened for inhibition of Abeta25-35 neurotoxicity toward the rat pheochromocytoma PC-12 cell line. The effect of the identified lead compounds on Abeta25-35 aggregation was then evaluated by means of circular dichroism (CD) and thioflavin-T fluorescence spectroscopy. Their activity against Abeta1-42 neurotoxicity toward the PC-12 cell line was also determined. The most active imidazopyridoindoles inhibited both Abeta25-35 and Abeta1-42 neurotoxicity in the low- to mid-micromolar range. Furthermore, inhibition of the random coil to beta-sheet transition and self-aggregation of Abeta25-35 was observed by CD and fluorescence spectroscopy, supporting the relationship between inhibition of the Abeta aggregation process and neurotoxicity. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940229     DOI: 10.1006/jsbi.2000.4245

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  5 in total

1.  Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils.

Authors:  Jan Bieschke; Martin Herbst; Thomas Wiglenda; Ralf P Friedrich; Annett Boeddrich; Franziska Schiele; Daniela Kleckers; Juan Miguel Lopez del Amo; Björn A Grüning; Qinwen Wang; Michael R Schmidt; Rudi Lurz; Roger Anwyl; Sigrid Schnoegl; Marcus Fändrich; Ronald F Frank; Bernd Reif; Stefan Günther; Dominic M Walsh; Erich E Wanker
Journal:  Nat Chem Biol       Date:  2011-11-20       Impact factor: 15.040

Review 2.  Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease.

Authors:  Fernanda G De Felice; Sérgio T Ferreira
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

Review 3.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Treatment strategies targeting amyloid β-protein.

Authors:  Dale Schenk; Guriqbal S Basi; Menelas N Pangalos
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

5.  Structure of amyloid β25-35 in lipid environment and cholesterol-dependent membrane pore formation.

Authors:  Nabin Kandel; Jason O Matos; Suren A Tatulian
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.